Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417259 | 0.87 | MAPT (0.48) | ALDH1A1LMNAMAPTTP53HTR6 | |
| SCHEMBL6418208 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KMT2ALMNAMAPTMEN1 | |
| SCHEMBL18854912 | 0.81 | KMT2A (0.66) | ALDH1A1KMT2ALMNAGAAKDM4E | |
| SCHEMBL19561830 | 0.76 | ALDH1A1 (0.73) | ALDH1A1KMT2ALMNAMAPTNAMPT | |
| SCHEMBL6488791 | 0.75 | KMT2A (0.58) | ALDH1A1KMT2ALMNAGAAKDM4E | |
| SCHEMBL21657707 | 0.75 | KMT2A (0.54) | ALDH1A1KMT2ALMNAGAAMAPT | |
| SCHEMBL6493236 | 0.74 | KDM4E (0.57) | ALDH1A1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL27739890 | 0.74 | KMT2A (0.65) | ALDH1A1KMT2ALMNAGAAMAPT | |
| SCHEMBL6481851 | 0.74 | KMT2A (0.59) | ALDH1A1KMT2ALMNAGAAKDM4E | |
| SCHEMBL2607644 | 0.73 | KMT2A (0.67) | KMT2ALMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | ALDH1A1 360/4885KMT2A 1284/4885LMNA 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.